Le Lézard
Classified in: Health
Subjects: PDT, HSP, ASI, BLK, NTA, MAT, DEI

Eighty Six Enters the Legal Psychedelics Market With Launch of Fun Guy Amanita Mushroom Gummies


TULSA, Okla., Feb. 22, 2023 /PRNewswire/ -- Oklahoma based alternative cannabinoid brand Eighty Six jumps on the burgeoning psychedelics market with the launch of Fun Guy, an edibles series dedicated to helping you experience a lighter, brighter, psychedelic trip.

Curious consumers all over the country now have access to a lighter, brighter psychedelic trip with Fun Guy.

Fun Guy enters the market with three classic flavors ? BlueRazz, Strawberry, and Watermelon.  Each gummy contains 350mg of Amanita Muscaria, a federally legal medley of mushrooms that deliver a chilled-out psychoactive experience.

What are Amanita Mushrooms?

Amanita mushrooms, otherwise known as  the Amanita Muscaria, is an easily recognizable red mushroom dotted with white specs on its cap. The mushroom contains muscarine and ibotenic acid, both of which convert to muscimol when consumed directly or is decarboxylated into a finished product. The experience mimics the effects of a classic "magic mushrooms" trip.

What Does a Milder Psychedelic Trip Look Like with Amanita Mushrooms?

The typical psychedelic trip from traditional "magic mushrooms" contain psilocybin, whose hallucinogenic properties interact with serotonin and dopamine neurotransmitters. The result is an intense and long-lasting trip that may or may not turn sour depending on your state of mind.

Amanita mushrooms, on the other hand, break down into muscimol to interact with GABA receptors. Due to the abundance of GABA receptors and its ability to affect the central nervous system, the psychoactive experience, while significantly milder, can vary from person to person. A single, 350mg dose of Amanita mushrooms is roughly the equivalent of 100mg of psilocybin, with one dose delivering whole-body relaxation and improved sleep quality, and higher doses potentially producing spontaneous sensation, visual distortions, and at times synesthesia ? read: hallucinations.

How is a Hallucinogenic Substance Legal?

Similar to how Delta-8 THC's legal status exists through a loophole in the 2018 Farm Bill, Amanita mushrooms' legal status exists through a loophole on the Controlled Substances list. Psilocybin is a Schedule I controlled substance, illegal to possess and distribute.  Amanita muscaria, muscimol, and ibotenic acid, all of which produce that milder psychedelic high, are not on said list. 

Amanita mushrooms are federally legal in all but one state ? Louisiana. Legislative loopholes are not a new thing, but are commonplace in the ever-expanding active ingredients industry. 

Company Information

Eighty Six has established itself as one of the most popular alternative products brands, making a name for itself in the hemp-derived cannabinoids space over the last three years with its flavor-based Delta-8 THC, HHC, and THC-O inhalable products. The inclusion of Fun Guy Amanita Mushroom Gummies shows the brand's commitment to being at the forefront of introducing premium, cutting edge products to a growing demographic of curious consumers looking for that perfect buzz.

SOURCE Eighty Six Group


These press releases may also interest you

at 09:10
Turner Construction Company is pleased to announce that it has agreed to acquire 100 percent of Dornan Engineering Group, a specialist mechanical, electrical, instrumentation and commissioning engineering contractor with operations in Ireland, the...

at 09:10
Masimo will release second quarter 2024 financial results for the period ended March 30, 2024, after the market closes on Tuesday, August 6, 2024. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted...

at 09:10
Concentric Analgesics, Inc., a clinical-stage biopharmaceutical company developing novel, non-opioid pain therapeutics, today announced publication of a multicenter, randomized clinical trial evaluating vocacapsaicin on the cover of the August 2024...

at 09:05
Eclipse Bioinnovations, Inc. (Eclipsebio), the leading RNA genomics company developing and commercializing novel, data-driven technologies and analyses that interrogate RNA, today announced the launch of its proprietary eMERGEtm platform. eMERGE is...

at 09:05
Dr. Vince Clinical Research (DVCR), a full-service contract research organization (CRO) specializing in early-phase clinical trials, is pleased to announce "Accelerating Clinical & Drug Development Timelines with AI," an exclusive webinar exploring...

at 09:04
Inimmune, a clinical stage biotech company focused on the development of novel immunotherapies, vaccines, and vaccine adjuvants announced today the dosing of the first patient in its Phase 1 single ascending dose study of INI-4001 in patients with...



News published on and distributed by: